APR 1 4 7006

AVE TRAC

PTO/SB06a (07-30)
Approved for use through 07/51/2006, M665-10031
U.S. Patent and Trademark Office; U.S. DEPARTINENT OF COMMERCE
the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unites; its displays a valid OMB control number,

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2 Attorney Docket Number

pond to a collection of information unless it displays a valid OMB control number						
Co	Complete if Known					
Application Number	10/563,031					
Filing Date	12/30/2005					
First Named Inventor	Alonso Fernandez, et al.					
Art Unit	Not yet assigned					
Examiner Name	Not yet assigned					
Attorney Docket Number	4258-117					

			U.S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number - Kind Code ^{2 (f Anown)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US- 5,578,325 A	11-26-1996	Domb, Abraham J., et al.	
	AB	US- 5,962,566 A	10-05-1999	Grandfils, Christian, et al.	
	AC	US- 4,904,479 A	02-27-1990	Illum, Lisbeth	1
	AD	US- 2002/0009493 A1	01-24-2002	Schwendeman, Steven P., et al.	
	AE	US- 6,465,425 B1	10-15-2002	Tracy, Mark A., et al.	
	AF	US- 2003/0059465 A1	03-27-2003	Unger, Evan C., et al.	
		US-			

	FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (ill known)	Publication Date MM- DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	™
	AG	WO96/20698 A2	07-11-1996	Levy, Robert J., et al.		
						-
					1	

Examiner		Date	
Signature		Considered	

Signature | E-XAMIMER | mileal if reference considered, whether or not cliation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of his form with next communication to applicant. "Applicants unique clation designation number (optional)." See Kinds Codes of USPTO Planta Draceroments at two-conformation of the communication of the communication of the communication of the communication of the object of the communication number (optional). "See Kinds Codes of USPTO Planta Draceroments at the object of the communication of the co

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USFTO to process) an application. Confidentiality is governed by 39 U.S. C.122 and 37 CFR 1.14. This collection is settlened to Downs to complete, including gathering, preparing, and submitting the completed application form to the USFTO. Then will vary depending upon the individual case. Any comments on the annuant of time you require to complete this form andors suggestions for reducing this budges, should be sent in chieful and officer. U.S. Patient and Trademark Office, U.S. Patient of Comments of the Complete this form and officer. U.S. Patient and Trademark Office, U.S. Patient of Comments of the Complete this form and officer. U.S. Patient of Comments of the Complete this form and officer. U.S. Patient of Comments of the Complete this form and officer. U.S. Patient of Comments of the Complete this form and officer. U.S. Patient of Comments of the Complete this form and the Complete thi

PTO/SB/08b (07-05)

Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Substitute for form 1449B/PTO Complete if Known Application Number 10/563,031 Filing Date 12/30/2005 INFORMATION DISCLOSURE First Named Inventor Alonso Fernandez, et al. STATEMENT BY APPLICANT Art Unit Not yet assigned (Use as many sheets as necessary) Examiner Name Not yet assigned Sheet 2 2 Attorney Docket Number 4258-117

of

NON PATENT LITERATURE DOCUMENTS					
Examine r initials No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (magazine, journal, serial, symposium, catalog, etc.), date, page(5), volume-issue number(s), publisher, city country where published.		T²			
	АН	BLANCO, M.D., ET AL. Development and characterization of protein-loaded polyllactide-co-glycolide) nanospheres, Eur. J. Pharm. Biopharm., June 1997, Page(s) 287-294, Volume 43, Number 3			
	AI	BLANCO, DOLORES, ET AL., Protein encapsulation and release from poly(lactide-co-glycolide) microspheres: effect of the protein and polymer, Eur. J. Pharm. Biopharm., May 1996, Page(s) 255-294, Volume 45, Number 3			
	AJ	HAWILEY, ANN E., ET AL., Lymph node localisation of biodegradable nanospheres surface modified with poloxamer and poloxamine block co-polymers, FEBS Letters, January 6, 1997, Pege(s) 319-323, Volume 400, Number 3			
	AK	KABANOV, ALEXANDER V., ET AL., Pluronic® block copolymers as modulators of drug efflux transporter activity in the blood-brain barrier, Adv. Drug Deliv. Rev., January 21, 2003, Page(s) 151-164, Volume 55, Number 1			
	AL	LEMIEUX, P., ET AL., A combination of poloxamers increases gene expression of plasmid DNA in skeletal muscle, Gene Therapy, June 2000, Page(s) 986-991, Volume 7, Number 11			
	AM	LOURENCO, CHRISTINA, ET AL., Steric stabilization of nanoparticles: Size and surface properties , Int. J. Pharm., July 12, 1996, Page(s) 1-12, Volume 136, Number 1			
	AN	MOGHIMI, S.M., ET AL., Surface engineered nanospheres with enhanced drainage into lymphatics and uptake by macrophages of the regional lymph, FEBS Letters, May 9, 1994, Page(s) 25-30, Volume 344, Number 1			
	AO	SANCHEZ, ALEJANDRO, ET AL., Development of biodegradable microspheres and nanospheres for the controlled release of cyclosponin A, Int. J. Pharm., October 15, 1993, Page(5) 263-273, Volume 99, Number 2-3			
	AP	SANCHEZ, ALEJANDRO, ET AL., Biodegradable micro- and nanoparticles as long-term delivery vehicles for interferon-alpha, Eur. J. Pharm. Sci., March 2003, Page(s) 221-229, Volume 18, Number 3-4			
	AQ	TOBIO, MARIA, ET AL., A Novel System Based on a Poloxamer/ PLGA Blend as a Tetanus Toxoid Delivery Vehicle, Pharm. Res., May 1999, Page(s) 882-688, Volume 16, Number 5			

Examiner	/Nissa Westerberg/	Date	03/18/2008
Signature	A Hood Trodiciborgi	Considered	00/10/2000

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete. including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Deartment of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.